High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
Oncology
1
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Vaccine
1100%
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2023
2024
2025
2026
IO BiotechPD-L1/IDO Peptide Vaccine
Clinical Trials (1)
Total enrollment: 30 patients across 1 trials
IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer
Start: Apr 2023Est. completion: Dec 202630 patients
Phase 1Recruiting
Related Jobs in Oncology
Senior Research Associate, Immuno-Oncology
SystImmune
9m ago
$60K - $85K/yr
Research Associate I/II, Immuno-Oncology
SystImmune
9m ago
Office Administrator
SystImmune
10m ago
$60K - $80K/yr
Scientist/Sr Scientist
TwoStep Therapeutics
San Carlos
20m ago
Working Student Office Management Support (m/f/d)
Mindpeak
Hamburg
24m ago
Senior Medical Project Manager (m/f/d)
Mindpeak
Hamburg
24m ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 30 patients
1 companies competing in this space